Law.com: UC criminologist explains risk assessment tools
Risk assessment tools are used across the U.S. to assign scores to defendants or convicted offenders based on the likelihood they will recommit crimes, fail to appear at pretrial hearings or commit a crime before those hearings. But, implemented in different jurisdictions, the same risk assessment tool can yield vastly different results, reports Law.com. Helping to shed light on the seeming discrepancy is University of Cincinnati criminologist Ed Latessa, a professor of criminal justice in the College of Education, Criminal Justice, and Human Services.
One common misconception about assessment tools is that they predict an individual’s recidivism or pretrial risk, Latessa explains. In reality, “they‘re not predicting [an] individual, they’re predicting a group,” said Latessa, who helped develop the Ohio Risk Assessment System (ORAS).
He adds, “A judge thinks if you’re standing in front of them and you scored low risk, you’re not going to [recidivate]. No—that just means you’re in a group with a low percentage of failure.”
Read the full story here.
Featured image at top: Handcuffs stock image, provided by Law.com
Related Stories
WLWT: Tips to fight off bad allergy symptoms
April 18, 2024
The University of Cincinnati's Ahmad Sedaghat spoke with WLWT about how Cincinnati's geography tends to make allergy symptoms worse and tips to fight off those symptoms.
UC’s Ground Floor Makerspace births combat robots
April 17, 2024
In the heart of UC's 1819 Innovation Hub lies the Ground Floor Makerspace, an advanced and active hub of ingenuity where students, faculty and the community converge to bring their ideas to life. This includes being the birthplace of robots much like miniature race cars, combating fender to fender in an enclosed boxing ring. Combat robots like UC's Maximizer will again be fighting for first place in the National Havoc Robot League (NHRL) competition, slated for April 20.
Medscape: Skin adverse events rare after immunotherapy to treat...
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.